Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Another Question, Dear Readers

David S. Pisetsky, MD, PhD  |  Issue: July 2007  |  July 1, 2007

We are embarking on a great experiment in the delivery of healthcare. Like all good experiments, this one has a hypothesis and the hypothesis is that we can improve care by offering providers incentives for quality. That is a very worthy goal, but the big and untested assumptions are that we can measure quality and that the incentives are sufficient to change behavior—to the extent that behavior needs to be changed. Of course, we can change the equation by reducing reimbursement for lack of quality, but let’s not go there right now.

At times like this, as I look at the future of my specialty, I feel like the patient who has gout. I am in fear. My anxiety is high and, in anticipation of the next attack (in this case, more regulations and bureaucracy), I worry that a wave of fearsome and flaming pain is rushing toward me.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

An I a realist or a Chicken Little when it comes to the future?

Please write in to [email protected]. You helped me on my last case. Now help me on this one.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Pisetsky is physician editor of The Rheumatologist and professor of medicine and immunology at Duke University Medical Center in Durham, N.C.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutQualityTreatment

Related Articles

    Colchicine: An Ancient Drug with Modern Uses

    August 11, 2021

    Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

    Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

    April 2, 2014

    Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered

    Colcrys Approval Triggers Questions

    May 1, 2010

    Some rheumatologists question the depth of research and the approval’s implications for patient access

    International Study Finds Colchicine Promising as Outpatient Treatment for COVID-19

    August 17, 2021

    One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences